Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 81% Improvement Relative Risk Ventilation 53% Discharge 74% c19early.org/d Nguyen et al. Vitamin D for COVID-19 Sufficiency Are vitamin D levels associated with COVID-19 outcomes? Retrospective study in the USA (July - October 2020) Lower mortality (p=0.0084) and higher discharge (p<0.0001) Nguyen et al., PLOS ONE, doi:10.1371/journal.pone.0268038 Favors vitamin D Favors control
25-hydroxyvitamin D is a predictor of COVID-19 severity of hospitalized patients
Nguyen et al., PLOS ONE, doi:10.1371/journal.pone.0268038
Nguyen et al., 25-hydroxyvitamin D is a predictor of COVID-19 severity of hospitalized patients, PLOS ONE, doi:10.1371/journal.pone.0268038
May 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 88 COVID-19 hospitalized patients and 122 controls, showing higher mortality, ventilation, and length of stay with vitamin D deficiency.
This is the 129th of 175 COVID-19 sufficiency studies for vitamin D, which collectively show higher levels reduce risk with p<0.0000000001 (1 in 18 vigintillion).
risk of death, 81.1% lower, OR 0.19, p = 0.008, cutoff 20ng/mL, adjusted per study, inverted to make OR<1 favor high D levels (≥20ng/mL), 25-OH-D3, multivariable, RR approximated with OR.
risk of mechanical ventilation, 52.8% lower, OR 0.47, p = 0.13, cutoff 20ng/mL, adjusted per study, inverted to make OR<1 favor high D levels (≥20ng/mL), 25-OH-D3, multivariable, RR approximated with OR.
risk of no hospital discharge, 74.0% lower, HR 0.26, p < 0.001, cutoff 20ng/mL, 25-OH-D3, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Nguyen et al., 3 May 2022, retrospective, USA, peer-reviewed, 11 authors, study period 15 July, 2020 - 15 October, 2020.
Contact: nguyen.nguyen2@bswhealth.org.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
25-hydroxyvitamin D is a predictor of COVID-19 severity of hospitalized patients
Nguyen N Nguyen, Muppala N P Raju, Briget Da Graca, Dapeng Wang, Nada A Mohamed, Manohar B Mutnal, Arundhati Rao, Monica Bennett, Matthew Gokingco, Huy Pham, Amin A Mohammad
PLOS ONE, doi:10.1371/journal.pone.0268038
Objectives Studies investigating the association between vitamin D and severity of COVID-19 have mixed results perhaps due to immunoassay assessment of total 25-hydroxyvitamin D (tD) (the sum of 25-hydroxyvitamin-D2 [25-OH-D2] and 25-hydroxyvitamin-D3 [25-OH-D3]). Liquid chromatography tandem mass spectrometry (LC-MS/MS) has high analytical specificity and sensitivity for 25-OH-D2 and 25-OH-D3, and thus enables a more accurate assessment of impact on COVID-19 outcomes. Methods We established reference intervals for 25-OH-D3 and tD using LC-MS/MS. 25-OH-D2, 25-OH-D3 and tD were quantitated for 88 COVID-19 positive and 122 COVID-19 negative specimens. Chi-square or Fisher's exact tests were used to test associations in binary variables. T-Tests or Wilcoxon rank sum tests were used for continuous variables. Cox proportional hazards were used to test associations between 25-OH-D3 or tD levels and length of stay (LOS). For mortality and ventilation, logistic regression models were used. Results COVID-19 patients with deficient (<20 ng/mL) levels of 25-OH-D3 had significantly longer LOS by 15.3 days. COVID-19 P patients with deficient (<20 ng/mL) and insufficient (<30 ng/ mL) of tD had significantly longer LOS by 12.1 and 8.2 days, respectively. Patients with insufficient levels of tD had significantly longer LOS by 13.7 days. COVID-19 patients with deficient serum 25-OH-D3 levels had significantly increased risk-adjusted odds of in-hospital mortality (OR [95% CI]: 5.29 [1.53-18.24]); those with insufficient 25-OH-D3 had significantly increased risk for requiring ventilation during hospitalization was found at LCMS insufficient cutoff (OR [95%
Supporting information S1 Table. Full models for adjusted evaluation of mortality, need for ventilation, and LOS. Full models for adjusted evaluation of mortality, need for ventilation, and LOS for COVID-19 positive patients at deficiency and insufficiency cutoffs for 25-OH-D3 and tD. Logistic regression was used for mortality and ventilation, and Cox proportional hazards was used for LOS.
References
Annweiler, Corvaisier, Gautier, Dube ´e, Legrand et al., Vitamin D supplementation associated to better survival in hospitalized frail elderly COVID-19 patients: the GERIA-COVID quasi-experimental study, Nutrients, doi:10.3390/nu12113377
Benton, Tetteh, Needham, Mu ¨cke, Sheppard et al., Evaluation of the 25-hydroxy vitamin D assay on a fully automated liquid chromatography mass spectrometry system, the Thermo Scientific Cascadion SM Clinical Analyzer with the Cascadion 25-hydroxy vitamin D assay in a routine clinical laboratory, Clin Chem Lab Med, doi:10.1515/cclm-2019-0834
Cascadiontm, 25-Hydroxy Vitamin D Assay
Castillo, Costa, Barrios, Alcala ´dı ´az, Lo ´pez Miranda et al., Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study, J Steroid Biochem Mol Biol, doi:10.1016/j.jsbmb.2020.105751
Daneshkhah, Agrawal, Eshein, Subramanian, Roy et al., Evidence for possible association of vitamin D status with cytokine storm and unregulated inflammation in COVID-19 patients, Aging Clin Exp Res, doi:10.1007/s40520-020-01677-y
Gauzzi, Purificato, Donato, Suppressive effect of 1alpha,25-dihydroxyvitamin D3 on type I IFN-mediated monocyte differentiation into dendritic cells: impairment of functional activities and chemotaxis, J Immunol, doi:10.4049/jimmunol.174.1.270
Giustina, Adler, Binkley, Consensus statement from 2 nd International Conference on Controversies in Vitamin D, Rev Endocr Metab Disord, doi:10.1007/s11154-019-09532-w
Gombart, Pierre, Maggini, A Review of Micronutrients and the Immune System-Working in Harmony to Reduce the Risk of Infection, Nutrients
Grant, Lahore, Mcdonnell, Baggerly, French et al., Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths, Nutrients
Heaney, Dowell, Hale, Bendich, Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D, J Am Coll Nutr, doi:10.1080/07315724.2003.10719287
Herna, Nan, Fernandez-Ayala, Garcı ´a-Unzueta, Herna ´ndez-Herna ´ndez et al., Vitamin D status in hospitalized patients with SARS-CoV-2 infection, The Journal of clinical endocrinology and metabolism
Hossein-Nezhad, Holick, Vitamin D for health: a global perspective, Mayo Clin Proc, doi:10.1016/j.mayocp.2013.05.011
Hossein-Nezhad, Spira, Holick, Influence of vitamin D status and vitamin D 3 supplementation on genome wide expression of white blood cells: a randomized double-blind clinical trial, PLoS One, doi:10.1371/journal.pone.0058725
Kaufman, Niles, Kroll, Bi, Holick, SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels, PLoS One, doi:10.1371/journal.pone.0239252
Lemire, Archer, Beck, Spiegelberg, Immunosuppressive actions of 1,25-dihydroxyvitamin D3: preferential inhibition of Th1 functions, J Nutr, doi:10.1093/jn/125.suppl%5F6.1704S
Meltzer, Best, Zhang, Vokes, Arora et al., Association of Vitamin D Status and Other Clinical Characteristics With COVID-19 Test Results, JAMA Netw Open, doi:10.1001/jamanetworkopen.2020.19722
Mohan, Cherian, Sharma, Exploring links between vitamin D deficiency and COVID-19, PLoS Pathog, doi:10.1371/journal.ppat.1008874
Murai, Fernandes, Sales, Pinto, Goessler et al., Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: a randomized clinical trial, Jama, doi:10.1001/jama.2020.26848
Nowson, Mcgrath, Ebeling, Vitamin D and health in adults in Australia and New Zealand: a position statement, Med J Australia, doi:10.5694/mja11.10301
Nurminen, Seuter, Carlberg, Primary Vitamin D Target Genes of Human Monocytes, Front Physiol, doi:10.3389/fphys.2019.00194
Radujkovic, Hippchen, Tiwari-Heckler, Dreher, Boxberger, Vitamin D deficiency and outcome of COVID-19 patients, Nutrients
Thacher, Clarke, Vitamin D Insufficiency, Mayo Clin Proc, doi:10.4065/mcp.2010.0567
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit